[CLSTR]
< Back to situations

[ORGANIZATION]

Novartis

Featured in 25 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [JP] [US] [CN]

Global pharmaceutical and oncology market growth projections

5 clusters · 7 sources · last updated

Latest: Global cancer therapy markets projected to grow significantly by 2030

The global pharmaceutical and oncology markets are projected to experience substantial growth through the early 2030s, driven by innovative therapies and advancements in diagnostics. While total pharmaceutical spending i

[ACTIVE] [BUSINESS] [CH] [US]

Novartis operational restructuring and market volatility

2 clusters · 4 sources · last updated

Latest: Novartis faces market decline following clinical research setbacks

Novartis has undergone significant operational and financial shifts. Initially, the company announced a strategic restructuring in Basel, Switzerland, involving the cutting of approximately 130 jobs. This plan includes p

[ACTIVE] [TECHNOLOGY] [KR] [AE] [EG]

South Korean medical tech and AI sovereignty expansion

4 clusters · 6 sources · last updated

Latest: South Korean tech firms develop specialized AI to ensure data sovereignty

South Korean medical technology and biotechnology companies are expanding their global footprint through specialized innovations and high-value technology exports. In the medical AI and device sectors, firms are securin

[ACTIVE] [BUSINESS] [DE] [US] [IR]

DAX volatility persists amid US-Iran escalation and rate-hic

15 clusters · 637 sources · last updated

Latest: Global markets react to rising oil prices and ECB interest rate hikes

The DAX index and broader European markets remain in a period of correction, driven by rising energy costs and interest rate speculation. Geopolitical tensions between the US and Iran have intensified, pushing Brent crud

[ACTIVE] [BUSINESS] [DE] [IT] [CH]

UniCredit and Commerzbank merger and regulatory progress

15 clusters · 107 sources · last updated

Latest: UniCredit gains 1.6 billion euros in capital via ECB approval

By early September 2026, the potential €43 billion takeover of Commerzbank by UniCredit has moved into a phase of intense negotiations with German regional and federal authorities. UniCredit has secured access to nearly

[ACTIVE] [POLITICS] [GR]

Greek political controversy over Kypseli child protection

2 clusters · 7 sources · last updated

Latest: SYRIZA demands reopening of investigation into Adonis Georgiadis

The SYRIZA-PS opposition party has called for institutional accountability from the Greek government regarding the Kypseli children case. The party’s Social Cohesion and Welfare sector is questioning the Minister of Soci

[ACTIVE] [HEALTH] [DE] [DK] [GR]

Inclisiran efficacy and evolving LDL cholesterol treatments

3 clusters · 9 sources · last updated

Latest: Cholesterol management: New study results and upcoming oral PCSK9 inhibitor

Research into the efficacy of inclisiran, a drug utilizing small interfering RNA (siRNA) technology to inhibit PCSK9 protein production, has demonstrated significant potential in reducing LDL cholesterol. An initial met

[ACTIVE] [BUSINESS] [CH] [US]

Novartis CAR T cell therapy trial suspensions

2 clusters · 34 sources · last updated

Latest: Novartis shares plunge following dual clinical trial failures

Novartis has halted eight clinical trials involving an experimental CAR T cell therapy following three deaths. The fatalities were linked to immune effector cell-associated hemophagocytic syndrome (IEC-HS), a condition w

[QUIET] [BUSINESS] [CH]

Novartis remibrutinib Phase III clinical trial results

2 clusters · 14 sources · last updated

Latest: Novartis reports positive Phase III results for oral MS drug remibrutinib

Novartis has reported positive topline results from two Phase III clinical trials, REMODEL-1 and REMODEL-2, evaluating its experimental oral drug remibrutinib for the treatment of relapsing multiple sclerosis. The drug,

[QUIET] [BUSINESS] [KR] [CH] [US]

Alteogen Hybrozyme technology licensing and commercial sales

3 clusters · 5 sources · last updated

Latest: Alteogen signs up to $3.2B licensing deal with Novartis

South Korean biotechnology firm Alteogen has expanded its Hybrozyme platform through significant licensing agreements. In August 2026, the company secured an exclusive licensing deal valued at up to $365 million with a g

[QUIET] [BUSINESS] [US] [CA] [CH]

Impact of U.S. drug pricing on international medicine access

2 clusters · 7 sources · last updated

Latest: U.S. drug pricing policy delays medicine rollouts in Canada

Pharmaceutical companies are delaying or cancelling the launch of new medications in international markets, specifically Switzerland and Canada, citing concerns over United States drug-pricing policies. In Switzerland,

Also covered in